Cancelmo Peter B sold $930K of OMER

Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.

Original reporting
SEC EDGAR · Cancelmo Peter B
Published Sep 1, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The sale reduces insider ownership, which some investors view as a negative signal, though the amount is modest relative to market cap.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

No 10b5-1 plan; the insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed post-market on Sep 1, 2026

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

VP and General Counsel Peter B. Cancelmo sold 50,000 shares for $929,667, reducing his stake to 200 shares.

Expected impact

Possible modest downward pressure in the near term.

Evidence & confidence

Large insider sell of ~0.5% of float, but no accompanying buyback or other catalyst.

Market effects

Minimal impact on the broader biotech sector.

Limited to US markets where OMER trades.

Low

Counterpoint

The sale could be unrelated to confidence, perhaps a tax or diversification move.

Key entities

  • Peter B. Cancelmo

    Vice President, General Counsel of OMEROS CORP

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q